SEER-2 NK study

I'm Interested!

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied:

Study Purpose

The purpose of this study is to find out the effectiveness of the (RGN-259) Thymosin Beta 4 eye drops solution in the clearing of a persistent epithelial defect (PED) (that is, consistent eye tissue breakdown) in subjects with Neurotrophic Keratopathy. RGN-259 is formulated as preservative-free, sterile eye drops and being studied to treat Neurotrophic Keratopathy. Since the tissue breakdown of the cornea is causing Neurotrophic Keratopathy, it is thought that this study treatment may help subjects with this disease by enhancing wound healing, repair and regeneration.